The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the adverse events (AEs) were ...
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the adverse events (AEs) were ...
1. The overall progression-free survival (PFS) was 10.54 years. 2. Patients with body mass weight (BMI) ≥ 24 derived greater ...
1. The median disease-free survival for gefitinib group and cisplatin/vinorelbine group was 35.9 and 25.1 months, respectively. 2. Patients receiving ...
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded ...
Image: PD 1. HLA-DRB1*07:01 and HLA-DQA1*02:01 are strongly associated with liver injury among patients with HER2+ primary breast cancer taking ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.